靶向胰腺癌基质治疗策略研究进展

周新源; 刘楠; 张盼; 霍美蓉

doi:10.11665/j.issn.1000-5048.20210602

靶向胰腺癌基质治疗策略研究进展

中国药科大学药学院药剂系，南京 210009

基金项目: 国家自然科学基金资助项目（No.82073175， No.81872424）

计量
- 文章访问数: 343
- HTML全文浏览量: 10
- PDF下载量: 505
出版历程
- 收稿日期: 2021-05-17
- 修回日期: 2021-06-01
- 刊出日期: 2021-12-24

Advances in research on therapeutic strategies of targeting pancreatic cancer stroma

Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China

Funds: This study was supported by the National Natural Science Foundation of China (No.82073175, No.81872424)

摘要

摘要: 胰腺癌基质在肿瘤进展、侵袭、转移和治疗抵抗中扮演着重要角色，单纯的靶向肿瘤细胞治疗策略已无法满足延长患者生存期的临床治疗需求。越来越多的研究着眼于靶向胰腺癌基质治疗与化疗、放疗和免疫疗法联合用药方案的开发。胰腺癌复杂的基质成分、互相串扰的信号通路和畸形增生的新生血管给靶向药物的研究开发带来了巨大挑战的同时也提供了相应的机遇。本文主要从细胞外基质（extracellular matrix，ECM）、肿瘤相关成纤维细胞（cancer associated fibroblasts，CAFs）和血管3个方面，综述了近期靶向胰腺癌基质治疗策略研究进展并加以分析讨论，以期为胰腺癌的靶向治疗提供新思路。
- 胰腺癌 /
- 靶向基质 /
- 细胞外基质 /
- 肿瘤相关成纤维细胞 /
- 抗血管新生 /
- 进展
Abstract: Pancreatic cancer stroma plays a critical role in tumor progression, invasion, metastasis and resistance.Targeting tumor cell alone could not meet the demand for prolonging patients'' survival.Growing studies have laid emphasis on developing combined regimens between targeting pancreatic cancer stroma and chemotherapy, radiotherapy and immunotherapy.We are faced with some new opportunities in spite of the great challenges brought to the research and development of targeting drugs owing to the complicated stroma components, crosstalking signal pathways and abnormal angiogenesis of pancreatic cancer.In this article, recent advances in therapeutic strategies of targeting pancreatic cancer stroma are reviewed and analyzed from the aspects of extracellular matrix (ECM), cancer associated fibroblasts (CAFs) and vessels, in the hope of providing some novel ideas for targeting therapy against pancreatic cancer.
- pancreatic cancer /
- targeting stroma /
- extracellular matrix /
- cancer associated fibroblasts /
- anti-angiogenesis /
- advances

HTML全文

参考文献(60)

[1]	. World J Gastroenterol，2018，24（19）：2047-2060.
[2]	Mizrahi JD，Surana R，Valle JW，et al. Pancreatic cancer［J］. The Lancet，2020，395（10242）：2008-2020.
[3]	Whatcott CJ，Diep CH，Jiang P，et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer［J］. Clin Cancer Res，2015，21（15）：3561-3568.
[4]	Provenzano PP，Cuevas C，Chang AE，et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma［J］. Cancer Cell，2012，21（3）：418-429.
[5]	Kalluri R. The biology and function of fibroblasts in cancer［J］. Nat Rev Cancer，2016，16（9）：582-598.
[6]	Bailey JM，Swanson BJ，Hamada T，et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer［J］. Clin Cancer Res，2008，14（19）：5995-6004.
[7]	Ohlund D，Handly SA，Biffi G，et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer［J］. J Exp Med，2017，214（3）：579-596.
[8]	Sun Q，Zhang B，Hu Q，et al. The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer［J］. Theranostics，2018，8（18）：5072-5087.
[9]	Shek F WT，Benyon RC，Walker FM，et al. Expression of transforming growth factor-β1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis［J］. Am J Pathol，2002，160（5）：1787-1798.
[10]	Ansari D，Carvajo M，Bauden M，et al. Pancreatic cancer stroma： controversies and current insights［J］. Scand J Gastroenterol，2017，52（6/7）：641-646.
[11]	Hosein AN，Brekken RA，Maitra A. Pancreatic cancer stroma： an update on therapeutic targeting strategies［J］. Nat Rev Gastroenterol Hepatol，2020，17（8）：487-505.
[12]	Brunetto E，De Monte L，Balzano G，et al. The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer［J］. J Immunother Cancer，2019，7（1）：45. doi：10.1186/s40425-019-0521-4.
[13]	Wang T，Notta F，Navab R，et al. Senescent carcinoma-associated fibroblasts upregulate il8 to enhance prometastatic phenotypes［J］. Mol Cancer Res，2017，15（1）：3-14.
[14]	Kadera BE，Li L，Toste PA，et al. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis［J］. PLoS One，2013，8（8）：e71978. doi：10.1371/journal.pone.0071978.
[15]	Tulla M，Pentikainen OT，Viitasalo T，et al. Selective binding of collagen subtypes by integrin alpha 1I，alpha 2I，and alpha 10I domains［J］. J Biol Chem，2001，276（51）：48206-48212.
[16]	Armstrong T，Packham G，Murphy LB，et al. Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma［J］. Clin Cancer Res，2004，10（21）：7427-7437.
[17]	Olivares O，Mayers JR，Gouirand V，et al. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions［J］. Nat Commun，2017，8：16031. doi： 10.1038/ncomms16031.
[18]	Chen D，Smith LR，Khandekar G，et al. Distinct effects of different matrix proteoglycans on collagen fibrillogenesis and cell-mediated collagen reorganization［J］. Sci Rep，2020，10（1）：19065. doi： 10.1038/s41598-020-76107-0.
[19]	Wong KM，Horton KJ，Coveler AL，et al. Targeting the tumor stroma： the biology and clinical development of pegylated recombinant human hyaluronidase （PEGPH20）［J］. Curr Oncol Rep，2017，19（7）：47. doi： 10.1007/s11912-017-0608-3.
[20]	Wegner CS，Hauge A，Gaustad JV，et al. Dynamic contrast-enhanced MRI of the microenvironment of pancreatic adenocarcinoma xenografts［J］. Acta Oncol，2017，56（12）：1754-1762.
[21]	Abyaneh HS，Regenold M，McKee TD，et al. Towards extracellular matrix normalization for improved treatment of solid tumors［J］. Theranostics，2020，10（4）：1960-1980.
[22]	Gallo N，Nasser H，Salvatore L，et al. Hyaluronic acid for advanced therapies：Promises and challenges［J］. Eur Polym J，2019，117：134-147.
[23]	Hingorani SR，Zheng L，Bullock AJ，et al. HALO 202：randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated，metastatic pancreatic ductal adenocarcinoma［J］. J Clin Oncol，2018，36（4）：359-366.
[24]	Zinger A，Koren L，Adir O，et al. Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors［J］. ACS Nano，2019，13（10）：11008-11021.
[25]	Ho WJ，Jaffee EM，Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities［J］. Nat Rev Clin Oncol，2020，17（9）：527-540.
[26]	Steele NG，Biffi G，Kemp SB，et al. Inhibition of hedgehog signaling alters fibroblast composition in pancreatic cancer［J］. Clin Cancer Res，2021，27（7）：2023-2037.
[27]	Chronopoulos A，Robinson B，Sarper M，et al. ATRA mechanically reprograms pancreatic stellate cells to suppress matrix remodelling and inhibit cancer cell invasion［J］. Nat Commun，2016，7：12630. doi： 10.1038/ncomms12630.
[28]	Kocher HM，Basu B，Froeling FEM，et al. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer［J］. Nat Commun，2020，11（1）：4841.
[29]	Shi X，Young CD，Zhou H，et al. Transforming growth factor-beta signaling in fibrotic diseases and cancer-associated fibroblasts［J］. Biomolecules，2020，10（12）：1666. doi：10.3390/biom10121666.
[30]	Ciardiello D，Elez E，Tabernero J，et al. Clinical development of therapies targeting TGFbeta：current knowledge and future perspectives［J］. Ann Oncol，2020，31（10）：1336-1349.
[31]	Melisi D，Garcia CR，Macarulla T，et al. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer［J］. Br J Cancer，2018，119（10）：1208-1214.
[32]	Ji T，Lang J，Wang J，et al. Designing liposomes to suppress extracellular matrix expression to enhance drug penetration and pancreatic tumor therapy［J］. ACS Nano，2017，11（9）：8668-8678.
[33]	Feng J，Xu M，Wang J，et al. Sequential delivery of nanoformulated alpha-mangostin and triptolide overcomes permeation obstacles and improves therapeutic effects in pancreatic cancer［J］. Biomaterials，2020，241：119907. doi： 10.1016/j.biomaterials.2020.119907.
[34]	Guo W，Chen W，Yu W，et al. Small interfering RNA-based molecular therapy of cancers［J］. Chin J Cancer，2013，32（9）：488-493.
[35]	Han X，Li Y，Xu Y，et al. Reversal of pancreatic desmoplasia by re-educating stellate cells with a tumour microenvironment-activated nanosystem［J］. Nat Commun，2018，9（1）：3390. doi： 10.1038/s41467-018-05906-x.
[36]	Lindquist JN，Parsons CJ，Stefanovic B，et al. Regulation of alpha1（I） collagen messenger RNA decay by interactions with alphaCP at the 3''-untranslated region［J］. J Biol Chem，2004，279（22）：23822-23829.
[37]	Li Y，Zhao Z，Lin CY，et al. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer［J］. Theranostics，2021，11（5）：2182-2200.
[38]	Kuninty PR，Bojmar L，Tjomsland V，et al. MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor［J］. Oncotarget，2016，7（13）：16396-16408.
[39]	Ho AS，Huang X，Cao H，et al. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer［J］. Transl Oncol，2010，3（2）：109-113.
[40]	Xie Y，Hang Y，Wang Y，et al. Stromal modulation and treatment of metastatic pancreatic cancer with local intraperitoneal triple miRNA/siRNA nanotherapy［J］. ACS Nano，2020，14（1）：255-271.
[41]	Zeltz C，Primac I，Erusappan P，et al. Cancer-associated fibroblasts in desmoplastic tumors： emerging role of integrins［J］. Semin Cancer Biol，2020，62：166-181.
[42]	Zeltz C，Alam J，Liu HS，et al. α11β1 integrin is induced in a subset of cancer-associated fibroblasts in desmoplastic tumor stroma and mediates in vitro cell migration［J］. Cancers，2019，11（6）：765. doi： 10.3390/cancers11060765.
[43]	Kota J，Hancock J，Kwon J，et al. Pancreatic cancer： stroma and its current and emerging targeted therapies［J］. Cancer Lett，2017，391：38-49.
[44]	Gunderson AJ，Yamazaki T，McCarty K，et al. Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma［J］. PLoS One，2019，14（2）：e0211117. doi： 10.1371/journal.pone.0211117.
[45]	Lo A，Li CP，Buza EL，et al. Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma［J］. JCI Insight，2017，2（19）：e92232. doi： 10.1172/jci.insight.92232.
[46]	Kraman M，Bambrough PJ，Arnold JN，et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha［J］. Science，2010，330（6005）：827-830.
[47]	Jiang GM，Xu W，Du J，et al. The application of the fibroblast activation protein α-targeted immunotherapy strategy［J］. Oncotarget，2016，7（22）：33472-33482.
[48]	Jackson HJ，Rafiq S，Brentjens RJ.Driving CAR T-cells forward［J］. Nat Rev Clin Oncol，2016，13（6）：370-383.
[49]	Benmebarek MR，Karches CH，Cadilha BL，et al. Killing mechanisms of chimeric antigen receptor （CAR） T cells［J］. Int J Mol Sci，2019，20（6）：1283. doi： 10.3390/ijms20061283.
[50]	Wang LC，Lo A，Scholler J，et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity［J］. Cancer Immunol Res，2014，2（2）：154-166.
[51]	Lo A，Wang LS，Scholler J，et al. Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells［J］. Cancer Res，2015，75（14）：2800-2810.
[52]	Chi J，Patel R，Rehman H，et al. Recent advances in immunotherapy for pancreatic cancer［J］. J Cancer Metastasis Treat，2020，6：43. doi： 10.20517/2394-4722.2020.90.
[53]	Folkman J. Tumor angiogenesis： therapeutic implications［J］. N Engl J Med，1971，285（21）：1182-1186.
[54]	Martin JD，Seano G，Jain RK. Normalizing function of tumor vessels： progress， opportunities， and challenges［J］. Annu Rev Physiol，2019，81：505-534.
[55]	Farnsworth RH，Lackmann M，Achen MG，et al. Vascular remodeling in cancer［J］. Oncogene，2014，33（27）：3496-3505.
[56]	Longo V，Brunetti O，Gnoni A，et al. Angiogenesis in pancreatic ductal adenocarcinoma： a controversial issue［J］. Oncotarget，2016，7（36）：58649-58658.
[57]	Gaustad JV，Simonsen TG，Wegner CS，et al. Vascularization，oxygenation，and the effect of sunitinib treatment in pancreatic ductal adenocarcinoma xenografts［J］. Front Oncol，2019，9：845. doi： 10.3389/fonc.2019.00845.
[58]	Li S，Xu HX，Wu CT，et al. Angiogenesis in pancreatic cancer： current research status and clinical implications［J］. Angiogenesis，2019，22（1）：15-36.
[59]	Katsuta E，Qi Q，Peng X，et al. Pancreatic adenocarcinomas with mature blood vessels have better overall survival［J］. Sci Rep，2019，9（1）：1310. doi： 10.1038/s41598-018-37909-5.
[60]	Ozdemir BC，Pentcheva HT，Carstens JL，et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival［J］. Cancer Cell，2014，25（6）：719-734.

施引文献(1)

期刊类型引用(0)

其他类型引用(1)

资源附件(0)

计量

文章访问数: 343
HTML全文浏览量: 10
PDF下载量: 505
被引次数: 1

靶向胰腺癌基质治疗策略研究进展

计量

出版历程

Advances in research on therapeutic strategies of targeting pancreatic cancer stroma

期刊类型引用(0)

其他类型引用(1)

计量

出版历程

目录